“We are very happy that the Italian Medicines Agency (Aifa) has given the green light to the reimbursement of trastuzumab deruxtecan, as monotherapy for the treatment of patients with Her2 low metastatic breast cancer”. Thus Rosanna D'Antona, president of Europa Donna Italia, during an event today in Milan on early diagnosis and targeted therapies for Her2 low metastatic breast cancer.
“This drug in fact, and we have seen it on a large number of women – he continues – prolongs the lives of patients and is able to guarantee them an acceptable quality of life. So we are very happy to have given our contribution. For years Europa Donna Italia's role is that of spokesperson and bearer of interest for women with breast cancer and Aifa is obviously one of our interlocutors. Furthermore, we raise awareness among women and associations of this type of accessibility to medicines and therefore we are happy that today this information is celebrated.”
#Europe #Woman #39good #Aifa #reimbursement #Her2 #metastatic #breast #cancer #therapy39
